Clinical activity of tipifarnib in hematologic malignancies

Elias Jabbour, Hagop Kantarjian, Jorges Cortes

Research output: Contribution to journalArticle

Abstract

Farnesyltransferase inhibitors are a novel class of anticancer agents that competitively inhibit farnesyltransferase. Initially developed to inhibit the farnesylation that is necessary for Ras activation, their mechanism of action seems to be more complex, involving other proteins unrelated to Ras. Of the four classes of farnesyltransferase inhibitors, at least three agents have been investigated in hematologic malignancies. Tipifarnib (R-115777), an orally administered non-peptidomimetic farnesyltransferase inhibitor, has shown promising clinical activity. Preliminary results from clinical trials demonstrate enzyme target inhibition, an acceptable toxicity profile and promising evidence of clinical activity. Ongoing studies will better determine the mechanism of action of tipifarnib and the role of combination with other agents, defining its place in the therapeutic arsenal of hematologic disorders.

Original languageEnglish (US)
Pages (from-to)381-392
Number of pages12
JournalExpert Opinion on Investigational Drugs
Volume16
Issue number3
DOIs
StatePublished - Mar 1 2007
Externally publishedYes

Fingerprint

tipifarnib
Farnesyltranstransferase
Hematologic Neoplasms
Prenylation
Antineoplastic Agents
Clinical Trials
Enzymes
Proteins

Keywords

  • Farnesyltransferase inhibitors
  • Leukemia
  • Ras pathway
  • Signal transduction
  • Tipifarnib

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Clinical activity of tipifarnib in hematologic malignancies. / Jabbour, Elias; Kantarjian, Hagop; Cortes, Jorges.

In: Expert Opinion on Investigational Drugs, Vol. 16, No. 3, 01.03.2007, p. 381-392.

Research output: Contribution to journalArticle

Jabbour, Elias ; Kantarjian, Hagop ; Cortes, Jorges. / Clinical activity of tipifarnib in hematologic malignancies. In: Expert Opinion on Investigational Drugs. 2007 ; Vol. 16, No. 3. pp. 381-392.
@article{f0cd552c584743f581d39f33783ada6f,
title = "Clinical activity of tipifarnib in hematologic malignancies",
abstract = "Farnesyltransferase inhibitors are a novel class of anticancer agents that competitively inhibit farnesyltransferase. Initially developed to inhibit the farnesylation that is necessary for Ras activation, their mechanism of action seems to be more complex, involving other proteins unrelated to Ras. Of the four classes of farnesyltransferase inhibitors, at least three agents have been investigated in hematologic malignancies. Tipifarnib (R-115777), an orally administered non-peptidomimetic farnesyltransferase inhibitor, has shown promising clinical activity. Preliminary results from clinical trials demonstrate enzyme target inhibition, an acceptable toxicity profile and promising evidence of clinical activity. Ongoing studies will better determine the mechanism of action of tipifarnib and the role of combination with other agents, defining its place in the therapeutic arsenal of hematologic disorders.",
keywords = "Farnesyltransferase inhibitors, Leukemia, Ras pathway, Signal transduction, Tipifarnib",
author = "Elias Jabbour and Hagop Kantarjian and Jorges Cortes",
year = "2007",
month = "3",
day = "1",
doi = "10.1517/13543784.16.3.381",
language = "English (US)",
volume = "16",
pages = "381--392",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - Clinical activity of tipifarnib in hematologic malignancies

AU - Jabbour, Elias

AU - Kantarjian, Hagop

AU - Cortes, Jorges

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Farnesyltransferase inhibitors are a novel class of anticancer agents that competitively inhibit farnesyltransferase. Initially developed to inhibit the farnesylation that is necessary for Ras activation, their mechanism of action seems to be more complex, involving other proteins unrelated to Ras. Of the four classes of farnesyltransferase inhibitors, at least three agents have been investigated in hematologic malignancies. Tipifarnib (R-115777), an orally administered non-peptidomimetic farnesyltransferase inhibitor, has shown promising clinical activity. Preliminary results from clinical trials demonstrate enzyme target inhibition, an acceptable toxicity profile and promising evidence of clinical activity. Ongoing studies will better determine the mechanism of action of tipifarnib and the role of combination with other agents, defining its place in the therapeutic arsenal of hematologic disorders.

AB - Farnesyltransferase inhibitors are a novel class of anticancer agents that competitively inhibit farnesyltransferase. Initially developed to inhibit the farnesylation that is necessary for Ras activation, their mechanism of action seems to be more complex, involving other proteins unrelated to Ras. Of the four classes of farnesyltransferase inhibitors, at least three agents have been investigated in hematologic malignancies. Tipifarnib (R-115777), an orally administered non-peptidomimetic farnesyltransferase inhibitor, has shown promising clinical activity. Preliminary results from clinical trials demonstrate enzyme target inhibition, an acceptable toxicity profile and promising evidence of clinical activity. Ongoing studies will better determine the mechanism of action of tipifarnib and the role of combination with other agents, defining its place in the therapeutic arsenal of hematologic disorders.

KW - Farnesyltransferase inhibitors

KW - Leukemia

KW - Ras pathway

KW - Signal transduction

KW - Tipifarnib

UR - http://www.scopus.com/inward/record.url?scp=33947171980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947171980&partnerID=8YFLogxK

U2 - 10.1517/13543784.16.3.381

DO - 10.1517/13543784.16.3.381

M3 - Article

C2 - 17302532

AN - SCOPUS:33947171980

VL - 16

SP - 381

EP - 392

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 3

ER -